Bridging the gap
Research

Research

Intravacc develops innovative platforms and methods to improve the effectiveness, stability and safety of vaccines.

Read More Close

Intravacc is continuously investing in R&D platforms to facilitate vaccine development. Early development includes vaccine strain design to generate bacterial, viral and cellular seeds for efficient vaccine production.

We also carry out studies on adjuvants and delivery systems, resulting in safe products that are efficacious.

Our successful R&D efforts are then further developed into services we offer to clients.

To investigate the efficacy of vaccines, Intravacc performs immunological research to unravel the mechanisms of action of vaccine concepts. These immunological assays are used during preclinical and clinical stages.    

 

Our expertise includes

  • Immunology
  • Molecular biology
  • Animal models
  • Systems vaccinology
  • Adjuvants
  • Vaccine delivery

 

 

 

 

Want to know more? Contact us at businessdevelopment@intravacc.nl

 

Process Development

Process Development

Intravacc develops bacterial and viral vaccines from discovery to phase II clinical trials. We use our own advanced technologies, such as Vero cell line and the OMV platform.

Read More Close

We can apply our long-standing and extensive experience in vaccine development to design rational and modelled processes together with our clients.

Using mathematical models we can safely scale from lab to commercial scale bioreactors.

 

Viral vaccine R&D

Focusing on the treatment or prevention of viral diseases such as Polio, Respiratory Syncytial Virus, Enterovirus, Influenza, Rabies and Rotavirus. We have access to a qualified Vero cell line and specialized equipment to perform research for WHO, the Dutch Ministry of Health and collaborate with other parties.

 

Bacterial Vaccine R&D

Focusing on Conjugate vaccine technology (for vaccines for Hib and Shigella) and Outer Membrane Vescicles (OMV) technology (Pertussis, Meningococcal B, Lyme disease and Tuberculosis research)

 

 

Main features

  • Established cGMP Vero cell line
  • Technology platform suitable for highly purified inactivated and live-attenuated vaccines
  • OMV-based vaccine technology platform suitable for heterologous antigen expression
  • State-of-the-art production technologies (including single-use and re-usable equipment)
  • Highly qualified BSL-2 and GxP trained personnel
  • Experience in Design of Experiments (DoE), and multiparametric data analysis
  • High-throughput methods for both Up-stream and Down-stream processing
  • Animal Component Free and Chemically Defined processing as standard methods
  • Tested processes to assure process robustness and reproducibility
  • Full panel of analytical capabilities for in-process controls
  • Scalable processes from 2 mL to pilot-scale and commercial manufacturing scale
  • Experience in Technology Transfer of vaccine production processes
  • CMC consulting capacities

 

Check out our factsheets:

Hand Foot Mouth Disease

Hib

Nonamen

OMVs

OMV Pertussis

RSV

Sabin IPV

Vero cells

 

Want to know more? Contact us at: businessdevelopment@intravacc.nl

Assays

Assays

Intravacc offers assay development and vaccine characterization services. We specialise in immunoassays, molecular biology methods, physicochemical analyses, and biological assays.

Read More Close

Assays to prove the quality of a new vaccine

The quality is a decisive factor in the development of new vaccines. Intravacc uses multiple instructive assays and innovative techniques to guarantee the quality of intermediates and finished product. Our tests focus on the composition, concentration, efficacy, purity, safety, stability and identity of the new vaccine candidate.

 

Immunoassays

  • ELISA (direct and capture assays for antibody titres in sera and antigen concentrations in vaccine formulations)
  • Multiplex Immunoassay (cytokines, antibody titres against multiple antigens, antigen concentrations in combination vaccines)
  • Biosensor analysis (epitope integrity, epitope mapping, affinity measurements, calibration free concentration analysis)
  • Immunoproteomics (identification of immunogenic proteins, B-cell epitopes and naturally processed T-cell epitopes by mass spectrometry)

 

Molecular biology methods

  • qPCR (quantification of viruses and bacteria by real time Polymerase Chain Reaction)
  • Deep sequencing (identity, sequence and genetic changes of viruses)

 

Physicochemical analyses

  • Mass spectrometry (identity, quantity, purity and chemical modifications of antigens, host cell proteins)
  • 2-D electrophoresis (antigen composition )
  • Fluorescence spectroscopy (conformation and aggregation of antigens)
  • Circular dichroism (secondary and tertiary structure of antigens)
  • Differential scanning calorimetry (denaturation temperature of antigens)
  • particle analysis by Dynamic Light Scattering (DLS), Field Flow Fractionation - Multiangle Laser Light Scattering (FFF-MALLS) 

 

Analytical techniques

  • HPLC (amino acid determination, residual phenol, monosaccharides, oligosaccharides, excipients)
  • GC (LPS analysis, phospholipids)
  • NMR (medium composition, metabolite analysis, chemical composition, impurities, excipients)

 

Biological assays

  • CCID50 (active virus titre)
  • Vero cell assay (residual toxin activity)

 

Want to know more? Contact us at: businessdevelopment@intravacc.nl

Animal models

Animal models

Intravacc is one of the leading players in global 3R research (reduce, replace and refine animal experiments).

Read More Close

We have developed several new methods, some of which were accepted by the European Pharmacopoeia.

In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in an IMI-funded European consortium on consistency testing.

 

Research focus:

  • Cell-based in vitro models, pysico-chemical techniques and immunochemical assays
  • Development of in-vitro assays
  • Transgenic mouse model for neurovirulence testing of OPV or Sabin-IPV lots

 

Achievements include:

  • Vero cell tests replacing the specific toxicity test in guinea pigs (diphtheria vaccine)
  • Serological tests replacing challenge procedures in potency testing (diphtheria and tetanus vaccine)
  • The use of human endpoints replacing lethal/severe clinical endpoints 

 

Check out our factsheet on our 3R research

 

Want to know more? Contact us at: businessdevelopment@intravacc.nl

Pilot-scale production

Pilot-scale production

Intravacc is home to a GMP facility for production of vaccines on pilot scale. This includes a state-of-the-art 100 m2 C/BSL-2 cleanroom.

Read More Close

Intravacc has years of experience in producing GMP batches for phase I and II clinical studies of viral and bacterial vaccines.

We have all the required equipment at our disposal for Upstream and Downstream Processing, including bioreactors of up to 100 liter.

This means we can offer a complete CTM production trajectory from seed lot production till released clinical batches.

 

Facilities

  • Fully adaptable cleanrooms
  • 100m2 class C/BSL-2 cleanroom for active processes
  • 25m2 class C cleanroom for inactive processes
  • Dedicated cleaning & sterilization department

 

Want to know more? Contact us at: businessdevelopment@intravacc.nl

Clinical & Regulatory

Clinical & Regulatory

Our inhouse clinical and regulatory scientists form part of each project team that develops a new vaccine. They offer regulatory support right from the start.

Read More Close

Innovative vaccines are mostly complex products for which there is often no clear regulatory guidance available. That is why our Regulatory and Clinical Affairs (RCA) team is involved in the development of these products right from the start.

By taking into consideration the regulatory restraints and requirements in an early phase of development, a lean transition to the next phase towards a marketed product can be made. 

Our team provides regulatory support in vaccine development projects through early involvement, assessment of potential regulatory requirements, preparation of risk assessments and by seeking informal or formal scientific advice with national competent authorities.

Support varies from the preparation of pharmaceutical, preclinical, and clinical development plans and reports, to the submission of relevant regulatory dossiers (IMPD/IND, CTA) to health authorities.

 

CMC activities

  • Raw materials assessment
  • Quality Target Product Profile-design, define product specifications
  • Gap analyses and risk assessments (e.g. Viral safety/TSE/Impurities/GMOs)
  • Design of program for stability testing
  • Comparability studies

Nonclinical

  • Pre-clinical evaluation of vaccine immunogenicity, efficacy
  • Coordination of non-clinical toxicology and safety studies
  • Non-clinical development plan

Clinical

  • Product Profile design
  • Clinical Development Pathway advise
  • Clinical study design
  • CRO selection and management

 

Want to know more? Contact us at: businessdevelopment@intravacc.nl

Co-Development with partners

Co-Development with partners

We are always open to work closely together with academia, public health organizations (WHO, BMGF), and biotech and pharmaceutical companies. This way, we benefit from each other's strengths in developing and innovating vaccines.

Read More Close

Are you looking for an experienced partner who can take your discovery to the next level of preclinical research?

Are you looking for a partner with GMP facilities, who can produce clinical lot material for your toxicity studies and phase I/II clinical trials?

Are you looking for a partner with a patent portfolio covering a variety of vaccine leads, novel vaccine technologies and adjuvants?

We are happy to discuss these and other possibilities for collaboration and co-development.

 

Vaccine concepts/technologies available for licensing

  • RSV
  • EV71
  • Pertussis
  • Alzheimer
  • LPS-mutants
  • Vero cells
  • MenB
  • Hib-conjugate vaccine

 

Want to know more? Contact us at businessdevelopment@intravacc.nl

About Intravacc

Intravacc is an experienced R&D organization with a proven track record in vaccinology of over 100 years. We have a wide range of expertise to independently develop vaccines from lead concept to clinical phase I/II studies as wel as our own product pipeline and patents.     

Read More Close
  • a wide range of science-based, one-stop-shop solutions
  • state-of-the-art facilities on site
  • Bacterial and Viral vaccines
  • OMV technology
  • Vero cell platforms
  • Innovative vaccine design
  • 3R research

Check out our factsheet on Intravacc 

Want to know more? Contact us at: businessdevelopment@intravacc.nl

 

 

 

 

 

FActsheet vaccine

Factsheets

News

Intravacc announces the establishment of ‘Intravacc B.V.’, preparing for its privatization

News | 01-02-2019

Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.

In May 2018, the Dutch Ministry of Health, Welfare and Sport announced the start of the privatization process of the activities of Intravacc a leading organisation in the field of vaccines research & development. As the privatization is progressing, the buyer of Intravacc is expected to be announced in the second quarter of 2019.

Preparing for the privatization, Intravacc B.V., a private company with limited liability, was established today. Once the shares of Intravacc are sold to the selected buyer, Intravacc B.V. will become operational and all assets, staff, intellectual property and contracts & agreements will be transferred to the new entity. This ensures a smooth transition of the business and the knowledge base of Intravacc with no interruption in servicing current customers.

Intravacc and CDBIO sign a research and license agreement to further develop and commercialize a Meningococcal B vaccine

News | 28-12-2018

Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.

Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.

Intravacc’s unique Nonamen® technology offers a broad panel of PorA proteins inserted in so called Outer membrane vesicles (OMV) expected to induce protection against the Meningococcal B (MenB) disease. Furthermore, the Nonamen® technology can be included in a Meningitis combination vaccine.

Under the agreement, both parties will collaborate to establish the development of an efficacious vaccine against prevalent Men B serotypes in China.

“We are very happy to partner with CDBIO and to be able to expand the global reach of our Nonamen technology. We trust this will help to prevent the occurrence of Men B in China considerably”, said Mr Nico Oudendijk, General Director of Intravacc.

 

Intravacc and BCHT enter into license agreement for production of a Hib conjugate vaccine

News | 12-11-2018

Intravacc and BCHT have entered into a non-exclusive license agreement for the development of a Hib conjugate vaccine within the People’s Republic of China.

Intravacc and Changchun BCHT Biotechnology Co today announced that they have entered into a non-exclusive license agreement towards the development ofa Haemophilus influenzae Type B (Hib) Conjugate Vaccine within the People’s Republic of China. By combining their strengths, the two parties can together lower the incidence of this vaccine preventable disease in China.

Through this agreement, BCHT obtained Intravacc’s unique Hib conjugate technology to further develop, produce and sell the vaccine. The vaccine consists of a Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled to tetanus toxoid that has shown to be effective in preventing the disease. The Intravacc Hib vaccine technology has already been used for the vaccination of 100s of millions of children.The license agreement between Intravacc and BCHT will now help to reduce the incidence of Hib in Chinese children.

Of the 6 types of H influenzae, type B is responsible for more than 90% of systemic infections. Hib can cause serious illness like acute lower respiratory tract infection and bacterial meningitis. In China, for children under age of 5 years old, the incidence of meningitis caused by Hib was reported in a survey about 10.7/100 000 annually; 9.7% of these cases were fatal, and 21.4% of survivors suffered from neurological or psychological problems. The agreement between Intravacc and BCHT will help to bring this number down considerably.

‘’It’s great to hear that the innovative work of our researchers at Intravacc will contribute to the prevention of Hib in China. We are proud to partner with BCHT to prevent this disease.” said Mr Nico Oudendijk, General Director of Intravacc.

Intravacc and TherapyX partner to develop world’s first prophylactic vaccine against Gonorrhea

News | 15-10-2018

Intravacc has entered into a strategic partnership with TherapyX for the co-development of the world’s first prophylactic vaccine to provide lasting, protective immunity against Neisseria gonorrhoeae.

Intravacc is pleased to announce that it has entered into a strategic partnership with TherapyX for the co-development of NGoXIMTM, the world’s first prophylactic vaccine against infection with Neisseria gonorrhoeae. This new vaccine is intended to enhance specific adaptive immune responses that provide lasting, protective immunity against N. gonorrhoeae. NGoXIMTM is a combination of a sustained-release formulation of interleukin 12 (GneX12TM) and bacterial outer membrane vesicles (OMV) formulated for mucosal delivery.

No effective gonorrhea vaccine is currently available and the disease is known to be acquired repeatedly with apparently no development of protective immunity from previous infection. The American Centers for Disease Control and Prevention (CDC) has listed antibiotic-resistant N. gonorrhoeae as one of the top three pathogens presenting “an immediate public health threat that requires urgent and aggressive action.” A recent WHO technical consultation on vaccines against sexually transmitted infections (2017) called for renewed efforts to develop a vaccine against gonorrhea. This partnership effort is a direct response to that call.

Under the terms of the partnership agreement, TherapyX will focus efforts on IND-enabling efficacy and toxicology studies in primates while Intravacc will be responsible for the discovery and development of OMVs with improved immunogenic properties and reduced toxicity. Financial terms were not disclosed.

“We are thrilled to partner with Intravacc” said Dr. Dominick L. Auci, Vice President for Research and Development at TherapyX. “They bring over 100 years of expertise in vaccines including novel OMV technology to this important project. We couldn’t be working with a more experienced, innovative and dedicated team”.

“We are delighted to be working with TherapyX” said Mr. Nico Oudendijk, General Director of Intravacc. “The IL-12 technology they bring into the project is key to develop an efficacious vaccine against this disease.”

 

Serum Institute of India and Intravacc to develop Bioneedles

News | 04-06-2018

  

New Delhi/Bilthoven, 29th May 2018: Life Sciences and Healthcare is a vital area of collaboration for India and the Netherlands.  Growing market opportunities in India, combined with the Netherlands’ strengths in Healthcare, create excellent opportunities for Indo-Dutch partnerships that address shared societal challenges with smart solutions. One of the key healthcare challenges that are being turned into Indo-Dutch collaborative solutions is vaccine delivery.

Serum Institute of India and Intravacc (part of the Netherlands Ministry of Health, Welfare and Sports) will jointly develop a novel delivery system for vaccines: Bioneedles. The Bioneedle, a tiny biodegradable mini implant, is a unique approach with ground breaking potential to transform vaccination campaigns, especially in low and middle income countries. The parties will develop Bioneedles for vaccines against measles and rubella. The Memorandum of Understanding confirming their collaboration was signed in the presence of Mark Rutte, Prime Minister of the Netherlands, Sigrid Kaag, Dutch Minister for Foreign Trade and Development Cooperation, Bruno Bruins, Dutch Minister for Medical Care and Sports, Hans de Boer, CEO, Confederation of Netherlands Industry and Employers VNO-NCW, and H.E Alphonsus Stoelinga, Ambassador of the Netherlands to India, during the Netherlands Trade Mission to India last week. The signatories were Dr Suresh Jadhav, Executive Director, Serum Institute of India and Thijs Veerman, CEO, Intravacc.

“I am happy that this MoU was signed during The Netherlands Trade mission to India. The collaboration between SII and Intravacc is a good example of a cooperation in which companies from India and The Netherlands join forces to help improve health worldwide,” Bruno Bruins, Minister for Medical Care of The Netherlands was quoted as saying. 

 

Currently, vaccines are mostly administered through intramuscular or subcutaneous injection by needle and syringe. The use of needles however may cause pain and fear in vaccinated people, and  requires trained personnel, which is not always readily available in low and middle income countries.  Moreover, needle waste can be hazardous due to reuse and needle-stick injuries and, as a result, transmission of infectious diseases like hepatitis or HIV. To overcome these issues, numerous alternative vaccine administration devices and methods are currently being developed.

One of the most promising technologies in alternative vaccine delivery is a Bioneedle-based delivery device. “Vaccines play a critical role in public health globally- and for Intravacc, India is a vital market for partnerships in vaccine development. This project could potentially mark a major step towards vastly improved access to vaccines especially in low and middle income countries. We are very happy to be involved in such an innovative project with our Indian partner,” Thijs Veerman, CEO, Intravacc says.

Bioneedles are composed of a starch-like polymer, a product that is naturally degraded by the human body. The Bioneedle is administered by an implantation under the skin with an applicator. The Bioneedle matrix will degrade after implantation, which enables the release of the freeze dried vaccine. This reduces hazardous needle waste and results in a quick and pain-free delivery of the vaccine; it may even abolish the need for trained professionals to perform vaccinations – a huge benefit in developing countries where trained medical personnel is scarce. In addition, vaccines in Bioneedles are both freeze and heat stable and can be stored, transported and distributed outside any cold chain. Preclinical concepts of Bioneedles have been established with numerous vaccines, including tetanus, polio, influenza and hepatitis B. In all cases, Bioneedles filled with vaccine were able to induce potent systemic humoral immune responses against the respective antigen. Serum Institute of India and Intravacc will jointly develop Bioneedles for vaccines against Measles and Rubella. Intravacc will optimize the formulation of the vaccine and preparation of the Bioneedles and freeze drying process; Serum Institute of India will supply the MR vaccine. Both parties will search for a partner, preferably from India, for developing a suitable applicator device to administer the Bioneedles.
 

“We are now the world's largest vaccine manufacturer by number of doses produced. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute, saving millions of lives throughout the world,” says Dr Suresh Jadhav, Executive Director, Serum Institute of India. With this project we continue to build a sustainable, long-term partnership with Intravacc in our effort to manufacture affordable life-saving vaccines .”

All together this is a unique approach with ground breaking potential to transform vaccination campaigns, especially in the low and middle income countries.

Dutch Ministry of Health announces privatization of Intravacc

News | 14-05-2018

The Dutch Ministry of Health, Welfare and Sport has announced the start of the privatization process of the activities of Intravacc. Collegium Advisors is to act as lead advisor and co-ordinator of the privatization process.

Bilthoven, May 8th, 2018 - The Dutch Ministry of Health, Welfare and Sport (Ministerie van Volkgezondheid, Welzijn en Sport or MoH) has announced the start of the privatization process of the activities of Intravacc.

Intravacc (Institute for Translational Vaccinology) has a wide range of relevant expertise in independently developing vaccines from lead concept to clinical phase I/II studies, and has its own product pipeline and patents. Moreover, it provides and contracts R&D services to a range of public and private customers. During the last several decades, Intravacc has positioned itself as a global leader in the development of vaccines aiding in the eradication of Polio and has engaged in the research and development of bacterial and viral vaccines against, amongst others, Respiratory Syncytial Virus (RSV), Shigella, Rotavirus, Hib and DTP.

Intravacc was originally formed to perform public tasks concerning research and development of new vaccines resulting from the ambitions and objectives set out by the Dutch State. The company’s aim is to develop safe, effective and affordable vaccine concepts in order to find sustainable solutions to improve public health worldwide. Intravacc is located in Bilthoven, the Netherlands, where it operates state-of-the-art R&D and Good Manufacturing Practice (GMP) facilities for conducting vaccine research.

As a result of the increasing commercial focus of the organization and its close collaboration with the (global) pharmaceutical industry and Global Health parties such as the World Health Organization and the Bill and Melinda Gates Foundation, MoH decided Intravacc would be better suited in a private setting. In June 2015, the Minster of MoH informed the Dutch House of Representatives on its intent to privatize Intravacc and, has now obtained all required political approval to commence the privatization process in order to secure a suitable prospective buyer.

Collegium Corporate Finance and Valuation Advisors has been appointed to act as lead advisor to the MoH during the privatization of Intravacc. Collegium will aim to inform potential prospective buyers about the timelines and structure of the privatization process. Any contact and all expressions of interest with regards to the privatization process should be expressed via Collegium (Intravacc@CollegiumAdvisors.com).

Contact details: Collegium Corporate Finance and Valuation Advisors,
Joachim Schulz, Managing Director, Tel: +31-10 203 7856.
Correspondence address: Westplein 11, 3016 BM Rotterdam, The Netherlands.

 

Career

Would you like to join our team?

Career

Internships at Intravacc

Close

Internships at Intravacc

Would you like to contribute to developing safe and effective vaccines?

At Intravacc we often have possibilities for internships for relevant MBO-, HBO-, and WO students.

 

The practical work of vaccine development is divided in 4 departments. Are you looking for an interesting and challenging internship? Then check below to see what each department has to offer.

 

If you are interested please send an email to Human Resources: personeelszaken@intravacc.nl

Make sure your email includes the following information:

  • the department and expertise you are interested in
  • when and how long you want to have your internship
  • your CV

We will let you know if we have availability during the time requested.

 

Please note that you need to be vaccinated to access the laboratories. The necessary vaccinations will be provided by Intravacc free of charge.

Process Development Bacterial Vaccines (PDBV)

In this department we develop processes for the production of bacterial vaccines. Most bacterial vaccines developed by Intravacc are either outer membrane vesicles vaccines or conjugate vaccines against many different pathogenic microorganisms. During process development we focus on the cultivation of bacteria (upstream processing, USP) and the purification of the vaccine from the culture broth (downstream processing, DSP). Processes are developed and each unit operation is optimized.

To answer the research questions and to meet the deliverables you will, during your internship, work with shaker flasks and bioreactors (from 1L to 70L and multi reactor systems) for the USP. For the DSP you will work with centrifugation and filtration techniques, these include dead-end and tangential flow filtration as well as size exclusion chromatography.

For conjugation technologies you will purify polysaccharides and perform chemical reactions to conjugate these polysaccharides to carrier proteins. This work involves analytical equipment like HPLCs. The department has a state of the art laboratory well equipped for all the research performed.

We often have openings for internships in all expertises described above.

    

    

          

===========================================================         

Exploratory and Clinical Research (ECR)

In this department, we design, generate and test concept vaccines. Expertise represented in the department include molecular biology, virology, bacteriology, immunology and regulatory and clinical affairs.

For vaccine design we investigate which antigens are suitable to include in a vaccine:

  • From the pathogen perspective we for example analyze which antigens are conserved and might induce protection against several pathogen strains.
  • From the host perspective, we investigate how we can induce an effective immune response while minimizing side effects.
  • Finally, we investigate which pathogen characteristics could help optimizing vaccine yield, such as the ability of a bacterial strain to produce outer membrane vesicles or for a virus to optimize growth in our vero production cells.

This information is combined to design new bacterial, viral or cellular strains using molecular biological techniques. Next, these strains are tested in production processes by the process development departments and within ECR we study the efficacy and safety of these vaccines both in vitro and in vivo, using an array of immunological techniques. Of note, we strive to design new in vitro techniques that can replace animal experiments as much as possible.

Throughout the whole vaccine chain it is important to monitor the feasibility of a concept vaccine from a technical and economical, but also from a regulatory and clinical point of view. Since the product is meant to be used in healthy people, there are many criteria to be met and it is crucial to substantiate which choices have been made and why.

At ECR we often have openings for internships related to strain design and immunology.

Process Development Viral Vaccines (PDVV)

This department designs, develops and improves processes for production of viral vaccines. Disciplines in the department are:

  • In silico: mechanistic and statistical modeling for process understanding and reduction of experimental effort.
  • Upstream processing: development of culture strategies at different scales (from milliliters to hundreds of liters) and operational modes (like batch, fed-batch or perfusion) using several cell lines to produce a number of viruses.
  • Bioreactor characterization: understanding the bioreactor mass and energy transfer mechanisms for effective scale up and/or scale down. Assessment of alternative culture systems; and implementation of measures for proper evaluation of bioreactor performance.
  • Downstream processing: design of processes for purification of the target vaccine. This can include testing and optimization of unit operations like filtration, centrifugation, chromatography or inactivation.
  • High-throughput process development: use of platform approaches for fast screening and automation of upstream and downstream processes

This means that a broad range of internships are possible in the PDVV department. Ranging from working with cell culture using bioreactors, focusing on purification technologies using Äkta systems and in depth mathematical calculations using specialized software, but also establishing routines for various analysis methods like virus titration and ELISA. The department uses state-of the art equipment in recently renovated laboratories at BSL2/ML-II/MI-III level.

==============================================================

Analysis, Delivery and Formulation (ADF)

This department focuses on the development of analytical tests, stable formulation and appropriate methods for administration of (new) vaccines. To facilitate efforts throughout Intravacc, ADF is structured in the following expertise groups:

  • Biomolecular Mass Spectrometry – Mass spectrometry is used to identify and quantify proteins and LPS in vaccines, demonstrate (chemical) modifications in proteins and determine B and T cell epitopes in antigens.
  • Analytical Biochemistry – A vast array of immunochemical and molecular biological methods are used to identify antigens and determine their concentrations and activity.
  • Biophysics & Chemistry – The latest chemical synthesis and structural analysis tools are used to create vaccine components and characterize their biophysical properties.
  • Delivery & Formulation – New vaccines are composed to yield stable products that can be appropriately administered. Formulation of vaccines are investigated as liquid formulations or as solid formulations (freeze-drying, spray drying). Vaccine administration routes such as intranasal, intradermal or oral administration routes are also explored.
  • Quality Control - Investigational vaccines for use in clinical trials undergo scrutiny of validated assays.

We often have interesting internship assignments for students.

Onderzoeksmedewerker (INT123)

Close De afdeling ‘Exploratory and Clinical Research’ (ECR) van Intravacc zoekt een

Onderzoeksmedewerker (INT123)

Intravacc is een toegepast wetenschappelijk onderzoekinstituut dat onderzoek doet naar nieuwe vaccins. Door Intravacc worden enerzijds veelbelovende ideeën uit de wetenschap beschermd en verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Anderzijds wordt door Intravacc de beschikbare kennis op het gebied van vaccinontwikkeling en -productie ingezet om R&D opdrachten voor klanten uit te voeren.

Het instituut rekent zowel de (inter)nationale overheid als bedrijven, onder andere binnen de innovatieve farmaceutische industrie, tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd, dus volop in beweging

Onderzoeksmedewerker m/v

36 uur per week

Vacaturenummer INT123

 

Functie

De afdeling ECR ontwikkelt, analyseert en toetst vaccine oncepten door middel van pre-klinisch onderzoek. Hierbij ligt de nadruk op moleculaire biologie en immunologie. Binnen de afdeling ECR zijn wij op zoek naar een full time onderzoeksmedewerker immunologie.

 

Als onderzoeksmedewerker ben je verantwoordelijk voor het uitvoeren van experimentele werkzaamheden die betrekking hebben op het testen van de veiligheid en werkzaamheid van vaccins. Er wordt verwacht dat je je werkzaamheden voorbereidt in overleg met ervaren collega’s en dat je de experimenten zelfstandig uitvoert en nauwgezet documenteert, in zowel labjournaals als rapportages.

 

Het profiel

  • HBO opleiding, studierichting Biologie en Medisch Laboratoriumonderzoek (life sciences) of een vergelijkbare studierichting met een sterke immunologische achtergrond.
  • Kennis van/affiniteit met immunologische technieken en assays, zoals celkweek, ELISA, Elispot en flow cytometrie.
  • Belangstelling voor de ontwikkeling van vaccins en de bijbehorende kwaliteitsregimes zoals GMP.
  • Ervaring met het werken in een BSL 2 laboratorium is een pre.
  • Goede beheersing van de Nederlandse en Engelse taal in woord en geschrift.
  • Je bent zorgvuldig, kunt je werk goed organiseren en bent resultaat- en samenwerkingsgericht.
  • Een flexibele maar kritische werkhouding en goed in staat om zowel in teamverband als zelfstandig te werken.
  • Je bent bereid consignatiediensten te draaien.

 

Keywords

Vaccinontwikkeling, immunologie, celkweek, ELISA, flow cytometrie, Elispot

 

Aanbod

Het salaris is, afhankelijk van opleiding en relevante werkervaring, maximaal € 3.521,52 bruto per maand (BBRA-schaal 8) op basis van een volledig dienstverband (36-urige werkweek), exclusief 16,37% Individueel Keuze Budget.

 

De aanstelling zal plaatsvinden op basis van indeling Functiegebouw Rijk, Onderzoeksmedewerker. Het betreft een functie in tijdelijke dienst voor de duur van 1 jaar met uitzicht op vast dienstverband.

 

Informatie

Voor meer informatie kun je contact opnemen met mevr. dr. E. van Riet (T: 0307920504).

 

Solliciteren

Wij ontvangen je sollicitatie (o.v.v. vacaturenummer INT123) graag uiterlijk 30 januari 2020 digitaal via personeelszaken@intravacc.nl

 

Let op VWNW en interne kandidaten genieten de voorkeur.

 

Download de vacaturetekst (pdf)

 

Acquitisite naar aanleiding van deze vacature wordt niet op prijs gesteld.

Junior controller (INT122)

Close Binnen de afdeling Finance hebben wij een uitdagende functie voor een:

Junior controller (INT122)

Het Instituut voor Translationele Vaccinologie (Intravacc) is dé plek in Nederland met een breed toegankelijke en complete infrastructuur voor translationele vaccinonderzoek en -ontwikkeling. Op het instituut worden goede ideeën uit de wetenschap verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Het instituut rekent zowel de (inter)nationale overheid als diverse big pharma bedrijven tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd tot een publiek-private onderneming.

Binnen de afdeling Finance hebben wij een uitdagende functie voor een:

 

Junior controller m/v

36 uur per week

Vacaturenummer: INT122

 

Functieomschrijving

In de functie van Junior Controller ben je onderdeel van de Finance & Accounting groep van Intravacc, die zorg draagt voor de juiste en tijdige administratie en hierover rapporteert aan belanghebbenden binnen en buiten de organisatie. Je rapporteert aan de CFO.

 

In deze functie ben je verantwoordelijk voor de volgende taken:

Algemeen

  • Analyseert tussenrekeningen grootboek en voert correcties uit;
  • Verwerkt en analyseert urenverantwoording en stelt rapportages op;
  • Verwerkt memoriaalboekingen;
  • Ondersteunt bij de maandafsluiting;
  • Ondersteunt bij maken van rapportages en toewijzen goedkeuringen binnen ERP-pakket.

Projectmanagement

  • Voert projectadministratie;
  • Ondersteunt en adviseert inhoudelijk projectleiders bij het opstellen en actualiseren van financiële prognoses;
  • Schakelt met Project Office en vertaalt personele planning naar financiële forecast;
  • Ondersteunt bij de maand- en jaarafsluiting van de projectadministratie;
  • Stelt cost statements en controle dossiers op voor externe opdrachtgevers en accountants (zowel nationaal als internationaal).

 

Functie-eisen

Je bent een financiële medewerker met enkele jaren bedrijfservaring, opgedaan als assistent controller of junior (project) controller. Je beschikt over een financiële opleiding accountancy, bedrijfsadministratie of bedrijfseconomie op minimaal HBO niveau. Daarnaast beschik je over een uitstekend analytisch vermogen en je maakt financiële pakketten snel eigen. Excel kent weinig tot geen geheimen voor je, je bent accuraat en ziet verbanden tussen de cijfers. Je bent communicatief vaardig, zowel mondeling als schriftelijk. Je bent goed in staat financiële data om te vormen tot informatie voor belanghebbenden.

 

Arbeidsvoorwaarden

Het salaris is, afhankelijk van opleiding en ervaring, maximaal EUR € 3.521,52 bruto per maand (BBRA-schaal 8 per 1 januari 2020). Het salaris is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering.

De aanstelling zal plaatsvinden op basis van de indeling Functiegebouw Rijk, Adviseur bedrijfsvoering (schaal 8).

 

Informatie

Voor meer informatie over de functie kun je terecht bij de CFO van Intravacc, Rob van Zeeland, tel. 030- 7920 561.

 

Solliciteren

Wij ontvangen je sollicitatie graag uiterlijk 23 januari 2020 digitaal via personeelszaken@intravacc.nl

 

 Let op de VWNW en interne kandidaten genieten de voorkeur.

 

Download de vacaturetekst (pdf)

 

Acquisitie n.a.v. deze vacature wordt niet op prijs gesteld.

 

 

 

 

 

Projectleider m/v (INT121)

Close Intravacc zoekt een

Projectleider m/v (INT121)

Intravacc is een toegepast wetenschappelijk onderzoekinstituut dat humane vaccins ontwikkelt. Enerzijds worden veelbelovende ideeën uit de wetenschap verder ontwikkeld tot waardevolle vaccins. Anderzijds wordt door Intravacc de beschikbare kennis op het gebied van vaccinontwikkeling en -productie ingezet om R&D opdrachten voor klanten uit te voeren.

Het instituut rekent zowel de (inter)nationale overheid als bedrijven tot haar klanten. Komend jaar zal het instituut worden geprivatiseerd.

Projectleider m/v

36 uur per week

Vacaturenummer: INT121

 

Functie

Wij zijn op zoek naar een ervaren projectleider die verantwoordelijk is voor het managen van (grote) vaccin ontwikkelprojecten. De projecten kunnen de gehele ontwikkelketen omvatten of een deel daarvan: van proof-of-concept tot en met vroege klinische ontwikkeling. Je draagt zorg voor de planning, uitvoering en rapportage. Projectteams bestaan uit medewerkers van verschillende afdelingen. Je rapporteert aan de programmamanager(s) van programma’s waarin je projecten zijn ondergebracht. Je hiërarchisch leidinggevende is de CSO. Daarnaast onderhoud je contacten met afdelingshoofden die mensen en apparatuur beschikbaar stellen en over inhoudelijke deskundigheid beschikken. Grote projecten doorlopen verschillende stadia waarbij stage gating technieken worden toegepast. Opdrachtgevers zijn NGOs, vaccinproducenten, biotechnologiebedrijven en de eigenaar van Intravacc. Daarnaast wordt samengewerkt met academische centra en/of hun spin-out bedrijven.

 

Je bent verantwoordelijk voor:

  • Het tijdig en binnen budget opleveren van project deliverables
  • Opstellen van meerjarige projectplannen incl. risico analyse
  • Uitvoering van projecten volgens plan binnen budget
  • De samenwerking met de bij de projecten betrokken externe partijen
  • De projectrapportages
  • Voorbereiden en vastleggen van eventuele projectwijzigingen
  • Aansturing en ondersteuning van projectmedewerkers
  • Onderhouden van contacten met de opdrachtgever in samenspraak met de programmamanager

 

Functie-eisen

  • PhD met minimaal 3 jaar Projectmanagement ervaring of MSc met 6 jaar Projectmanagement ervaring
  • Ervaring op het gebied van vaccinologie, farma of biotechnologie
  • Ervaring met productontwikkeling van biologics (bij voorkeur met vaccins) tot en met de vroeg-klinische fase
  • Ervaring met GMP, bij voorkeur in een R&D-omgeving (late stage product development, productie van pilot scale GMP batches)
  • Goede communicatieve vaardigheden en ervaring in aansturen/leidinggeven aan grote/multidisciplinaire teams
  • Oplossingsgericht en in staat om beslissingen te nemen en te werken onder tijdsdruk
  • Goede schriftelijke en mondelinge uitdrukkingsvaardigheid in Engels en Nederlands

 

Aanbod

Het salaris is, afhankelijk van opleiding en relevante werkervaring, maximaal € 5671,10 bruto per maand (maximaal BBRA-schaal 12 per 1-1-2020). Het salaris is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering.

De aanstelling zal plaatsvinden op basis van de indeling Functiegebouw Rijk, Project-/Programmamanagement.

 

Informatie

Voor meer informatie over de functie kun je terecht bij de heer E. de Ridder, tel. 030 – 7920 521, e-mail erik.de.ridder@intravacc.nl.

 

Solliciteren

Wij ontvangen je sollicitatie graag uiterlijk 19 december 2019 digitaal via personeelszaken@intravacc.nl

 

Let op de VWNW en interne kandidaten genieten de voorkeur.

Download de vacaturetekst (pdf)

 

Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.

Visiting address | Antonie van Leeuwenhoeklaan 9 | 3721 MA | Bilthoven | The Netherlands
Postal Address | P.O. Box 450 | 3720 AL | Bilthoven | The Netherlands
Back To Top